Controversies in Using Off-Label Intravitreous Bevacizumab for Patients With Diabetic Macular Edema.
Department of Ophthalmology, University of South Carolina School of Medicine, Palmetto Retina Center, LLC, West Columbia.
W Lloyd
WL
Clark
Department of Ophthalmology, University of Southern California/Keck School of Medicine, Los Angeles3Retina Vitreous Associates, Los Angeles, California.
David S
DS
Boyer
Chaney Family Endowed Chair in Ophthalmology Research, Cole Eye Institute, Cleveland Clinic Foundation, Cleveland, Ohio.
Peter K
PK
Kaiser
D020533:Angiogenesis Inhibitors; D000068258:Bevacizumab; D003930:Diabetic Retinopathy; D006801:Humans; D058449:Intravitreal Injections; D008269:Macular Edema; D056687:Off-Label Use; D041623:Tomography, Optical Coherence; D042461:Vascular Endothelial Growth Factor A
D020533:Angiogenesis Inhibitors; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab